Elsevier

American Heart Journal

Volume 157, Issue 2, February 2009, Pages 352-360.e2
American Heart Journal

Clinical Investigation
Prevention and Rehabilitation
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

https://doi.org/10.1016/j.ahj.2008.09.022Get rights and content

Background

High-density lipoprotein cholesterol (HDL-C) levels are inversely associated with cardiovascular risk. Cholesteryl ester transfer protein inhibition is one strategy for increasing HDL-C. This study evaluated the lipid-altering efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy or coadministered with atorvastatin in patients with dyslipidemia.

Methods

A total of 589 patients with primary hypercholesterolemia or mixed hyperlipidemia (53.8% of the study population had low HDL-C) were randomized equally to one of 10 groups: 5 groups received background statin therapy of atorvastatin 20 mg and 5 did not, and each of these was randomized to placebo, anacetrapib 10, 40, 150, and 300 mg once daily for 8 weeks. An equal proportion of patients had triglycerides >150 mg/dL in each group.

Results

For placebo and anacetrapib monotherapy (10, 40, 150, and 300 mg), least squares mean percent changes from baseline to week 8 for low-density lipoprotein cholesterol (LDL-C) were 2%, −16%, −27%, −40%, and −39%, respectively, and for HDL-C were 4%, 44%, 86%, 139%, and 133%, respectively (P < .001 vs placebo for all doses). Coadministration of anacetrapib with atorvastatin produced significant incremental LDL-C reductions and similar HDL-C increases versus atorvastatin monotherapy. For both anacetrapib monotherapy and coadministration with atorvastatin, the LDL-C reductions were similar in patients with baseline triglyceride levels greater than and less than or equal to the median. Anacetrapib was well tolerated, and the incidence of adverse events was similar for placebo and all active treatment groups. There were no increases in systolic or diastolic blood pressure in any treatment arm.

Conclusions

Anacetrapib, as monotherapy or coadministered with atorvastatin, produced significant reductions in LDL-C and increases in HDL-C; the net result of treatment with anacetrapib + atorvastatin was ∼70% lowering of LDL-C and more than doubling of HDL-C. Anacetrapib was generally well tolerated with no discernable effect on blood pressure.

Section snippets

Study design

This was a multicenter (61 centers), randomized, double-blind, placebo-controlled, parallel-group dose-ranging study to assess the efficacy, safety, and tolerability of anacetrapib, administered as monotherapy or with atorvastatin 20 mg (Pfizer Pharmaceuticals, Ltd, New York, NY), in patients with primary hypercholesterolemia or mixed hyperlipidemia. After screening and placebo run-in, eligible patients were randomized via an interactive voice response system equally to one of 10 groups: 5

Baseline demographics and efficacy variables

Baseline demographic characteristics and efficacy variables of the randomized patients (n = 589) were similar across the 10 treatment groups (Table I; expanded Table I in Appendix A, available online). Overall, 53.8% of patients had low HDL-C levels (≤44 mg/dL in men and ≤54 mg/dL in women). The median baseline LDL-C for the overall population was 140.1 mg/dL. Median baseline aldosterone levels were 7.5, 0.0, and 8.8 ng/dL in the anacetrapib 40-, 150-, and 300-mg + atorvastatin 20-mg groups,

Discussion

Anacetrapib, a potent CETP inhibitor, was associated with substantial and significant dose-dependent decreases in LDL-C and increases in HDL-C, with no demonstrable increase in blood pressure. The maximal pharmacodynamic lipid effect resulted in decreases in LDL-C and apo B of ∼40% and ∼30%, respectively, and increases in HDL-C and apo A-I of 139% and 47%, respectively. At the top doses of anacetrapib (150 and 300 mg), the maximal reductions in LDL-C and apo B were similar to those with

References (25)

  • BarterP.J. et al.

    Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

    Arterioscler Thromb Vasc Biol

    (2003)
  • BarterP.J. et al.

    Effects of torcetrapib in patients at high risk for coronary events

    N Engl J Med

    (2007)
  • Cited by (232)

    • Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA)

      2021, Archives of Cardiovascular Diseases
      Citation Excerpt :

      Cholesteryl ester transfer protein (CETP) inhibitors have shown promising Lp(a)-lowering effects, involving a decrease in hepatic apo(a) production rate [160]. In the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) study, anacetrapib given in combination with statins decreased Lp(a) by 17% [161]. However, CETP inhibitors were either without effect or led to a minor reduction in Lp(a) concentrations [162], and they are not approved for clinical use.

    • Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes

      2019, Atherosclerosis
      Citation Excerpt :

      This relationship is thought to be largely mediated by the ability of HDL to transport excess cholesterol from peripheral tissues back to the liver for excretion, a process known as reverse cholesterol transport [2]. Potent cholesteryl ester transfer protein (CETP) inhibitors, like torcetrapib, evacetrapib and anacetrapib, significantly increase HDL-C and decrease LDL-C levels, as monotherapy and in combination with statins [3–6]. However, except anacetrapib [7], these lipoprotein changes have not resulted in reduction of major cardiovascular events (MACE) [8–10].

    View all citing articles on Scopus

    Registered Clinical Trial No.: NCT00325455.

    View full text